We deliver you hope and ability to escape of hepatitis C and leave this life experience behind you.

*
Fatigue, headache, and nausea were the most common adverse events. The incidence of adverse events was lower among patients receiving ledipasvir–sofosbuvir alone (67% and 69% of patients receiving 8 weeks and 12 weeks of treatment, respectively) than among those receiving 8 weeks of ledipasvir–sofosbuvir plus ribavirin (76%) (Table 3 Table 3 Treatment Discontinuations, Adverse Events, and Hematologic Abnormalities. ). Patients in the group that received ledipasvir–sofosbuvir plus ribavirin had higher rates of events that are generally associated with ribavirin therapy — fatigue, headache, nausea, insomnia, irritability, rash, pruritus, cough, and anemia — than did patients who received ledipasvir–sofosbuvir alone (Table 3 ). 15 A total of 2 patients (1%) receiving 8 weeks of ledipasvir–sofosbuvir, 8 (4%) receiving 8 weeks of ledipasvir–sofosbuvir plus ribavirin, and 7 (3%) receiving 12 weeks of ledipasvir–sofosbuvir had grade 3 (severe) or grade 4 (life-threatening) adverse events.
Drug: Simeprevir (SMV) Drug: Ledipasvir (LDV) Drug: Sofosbuvir (SOF)
www.alym.38kir.ru/index.php/forum/dobro-...-information-leaflet
This study will evaluate the safety, tolerability, and efficacy of GS-9857 plus sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) ± ribavirin (RBV) in adults with chronic genotype 1 hepatitis C virus (HCV) infection.
32Gane ED, Stedman CA, Hyland RH, et al . All-oral sofosbuvir-based 12-week regimes for the treatment of chronic HCV infection: the ELECTRON study. 48th Annual Meeting of the European Association for the Study of the Liver, April 24–28, 2013, Amsterdam, Netherlands; abstract 14.